Effectiveness of a Wilms tumour treatment guideline adapted to local circumstances in sub‐Saharan Africa: A report from Wilms Africa Phase II—CANCaRe Africa
Pediatric Blood & Cancer2024Vol. 71(11), pp. e31300–e31300
Citations Over TimeTop 16% of 2024 papers
Diriba Fufa, Cecilia Mdoka, Mulugeta Ayalew, Harriet Khofi, Emmanuel Amankwah, Nester Chokwenda, Esubalew Mezgebu, Annelies M. C. Mavinkurve‐Groothuis, Steve Kamiza, Beatrice Chikaphonya‐Phiri, Mulugeta Wassie, Barnabas Atwiine, Mushabe Branchard, Maite Gorostegui, Jeannette Parkes, Evaristar Kudowa, Bernice Eklu, Brian Jator, Lorna Renner, Eric Borgstein, Elizabeth Molyneux, Francine Kouya, Kathy Pritchard‐Jones, Vivian Paintsil, Inam Chitsike, George Chagaluka, Trijn Israëls
Abstract
Patients continue to present late with advanced WT in sub-Saharan Africa, and their survival is below the 60% GICC target. Prevention of treatment abandonment and treatment-related mortality remain important. Earlier diagnosis and access to radiotherapy are expected to decrease disease-related mortality.
Related Papers
- → Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour(2006)322 cited
- → Wilms tumour experience in a South African centre(2005)36 cited
- → Adult Wilms' Tumour: Case Report and Review of Literature(2016)26 cited
- → Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2(2000)58 cited
- Wilms Tumour with Intracardiac Extension.(2012)